Isotechnika Reports Final Safety and Efficacy Data From Phase III Psoriasis Extension Trial

Edmonton, Canada (ots/PRNewswire) - Isotechnika Inc. (TSX:ISA)
reports final safety and efficacy data subsequent to 60 weeks of
continuous treatment with ISA247. All safety and efficacy endpoints
were met.

Patients completing the 24 week Canadian Phase III SPIRIT trial
were given the opportunity to continue ISA247 therapy at a 0.3 mg/kg
twice daily oral dose for an additional 36 weeks. The goal of the
extension trial was to gather long term safety data while
demonstrating continued therapeutic benefit.

Patients have now received continuous treatment with ISA247 for a
total of 60 weeks. Over the course of the 24-week Phase III trial,
patients exhibited a 60% mean improvement in Psoriasis Area and
Severity Index (PASI) scores. After an additional 36 weeks of
treatment, there was a 54% mean improvement in PASI scores
indicating continued therapeutic benefit. This beneficial effect was
still observed twelve weeks after discontinuing ISA247 treatment;
mean PASI scores remained at 35% below pre-treatment scores.

Subsequent to 60 weeks of continuous treatment, there were no
clinically significant changes in kidney function, cholesterol,
triglycerides, new onset diabetes, infectious complications, or other
laboratory parameters. This supports the long term safety of ISA247.

"The heartening experience portending a new psoriasis medication
continues as the efficacy and safety are confirmed in a longer
study," stated Dr. Robert Auerbach, Clinical Professor of
Dermatology, New York University School of Medicine.

"We are pleased that the final 60 week data is consistent with all
previously reported data on the drug," added Dr. Randall Yatscoff,
Isotechnika's President & CEO. "The purpose of the extension trial
was to generate longer term safety and efficacy data. All of the
endpoints of this trial have been successfully achieved. In
addition, the majority of patients exhibited continued therapeutic
benefit subsequent to discontinuation of drug."

Dr. Yatscoff will present the final 60 week data at BioContact at
2:30 p.m. ET/12:30 p.m. MT this afternoon. All interested parties are
encouraged to view the presentation on the Company's corporate web
site at www.isotechnika.com. The presentation will be loaded onto
the web site in conjunction with Dr. Yatscoff's live presentation.

About Isotechnika

Isotechnika Inc. is an international biopharmaceutical company
headquartered in Edmonton, Alberta, Canada. Drawing upon its
expertise in medicinal chemistry and immunology, the Company is
focused on the discovery and development of novel immunosuppressive
therapeutics that are safer than currently available treatments. Its
entrepreneurial management and world- class team of scientists are
building a pipeline of immunosuppressive drug candidates for
treatment of autoimmune diseases and for use in the prevention of
organ rejection in transplantation. Isotechnika looks to become the
leader in development of immunosuppressant therapies.

Isotechnika's lead compound, ISA247 has successfully completed a
Canadian Phase III human clinical trial for the treatment of moderate
to severe psoriasis. ISA247 is currently being investigated in a
North American Phase IIb human clinical trial for the prevention of
kidney graft rejection. The Company also has an additional
immunosuppressive compound in its drug pipeline, TAFA93 which
successfully completed Phase I clinical trials.

Isotechnika Inc. is a publicly traded company on the Toronto Stock
Exchange under the symbol ISA. More information on Isotechnika can be
found at www.isotechnika.com.

Partnerships

Isotechnika Inc. signed a collaboration agreement with Hoffman La
Roche on April 9, 2002, which licensed the worldwide rights to
develop and commercialize ISA247 for all transplant indications.

On September 30, 2005, Isotechnika Inc. entered into an exclusive
worldwide licensing agreement with Atrium Medical Corporation for the
use of ISA247 and TAFA93 specifically with drug eluting devices for
the non- systemic treatment of vascular, cardiovascular, target
vessel and tissue disorders.

Isotechnika Inc. and Cellgate Inc. signed an option agreement on
April 25, 2006, granting Isotechnika the option to obtain an
exclusive license to develop and commercialize conjugates consisting
of Cellgate's patented transporter technology for the topical
delivery of ISA247 in patients suffering from mild to moderate
psoriasis.

On May 25, 2006, Isotechnika Inc. signed an agreement with Lux
Biosciences, Inc. of Jersey City, New Jersey granting Lux Biosciences
worldwide rights to develop and commercialize Isotechnika's lead
drug, ISA247 for the treatment and prophylaxis of all ophthalmic
diseases.

Forward-Looking Statements

This press release may contain forward-looking statements. Forward
looking statements, including the Company's belief as to the
potential of its products, the Company's expectations regarding the
issuance of additional patents and the Company's ability to protect
its intellectual property, involve known and unknown risks and
uncertainties, which could cause the Company's actual results to
differ materially from those in the forward looking statements. Such
risks and uncertainties include, among others, the availability of
funds and resources to pursue research and development projects, the
ability to economically manufacture its products, the potential of
its products, the success and timely completion of clinical studies
and trials, the Company's ability to successfully commercialize its
products, the ability of the Company to defend its patents from
infringement by third parties, and the risk that the Company's
patents may be subsequently shown to be invalid or infringe the
patents of others. Investors should consult the Company's quarterly
and annual filings with the Canadian commissions for additional
information on risks and uncertainties relating to the
forward-looking statements. Investors are cautioned against placing
undue reliance on forward-looking statements.

ots Originaltext: Isotechnika Inc.
Im Internet recherchierbar: http://www.presseportal.de

Contact:
For further information: Dr. Randall Yatscoff, President & CEO,
Isotechnika Inc.,
+1-(780)-487-1600 (246), +1-(780)-484-4105 (fax),
ryatscoff@isotechnika.com; Stephanie Gillis-Paulgaard, Director,
Corporate Communications, Isotechnika Inc., +1-(780)-909-4661,
+1-(780)-484-4105 (fax), sgillis-paulgaard@isotechnika.com